Interchangeable Biosimilar Automatic Substitution : vimarsan

Interchangeable Biosimilar Automatic Substitution

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Related Keywords

Kimberlyc Chen , Jonathan Kay , Ryan Haumschild , , Interchangeable Biosimilar , Automatic Substitution , Biosimilars , Pharmacy , Payer Perspective , Reference Product , Financial Concerns , Clinical Concerns ,

© 2025 Vimarsana